Protein Diagnostics Market Booms, Registers CAGR of 5.4% to Reach Staggering Valuation of US$ 8.3 Billion by 2033 | FMI

As per Future Market Insights’ latest industry analysis, the valuation for the global Protein Diagnostics Market was around US$ 4.7 Billion in 2022 and is projected to exhibit a CAGR growth of close to 5.4% over the forecast period, with an estimated valuation of US$ 8.3 Billion in 2033.

According to the European Union 2020, medical diagnostic tests, with the aim of diagnosing a disease or verifying its presence, provide the basis of over 75% of clinical decisions. Early diagnosis is the process of using new and developing technologies to identify diseases sooner than expected. Early diagnosis is receiving a greater degree of attention in the medical community. Enhancing care quality, expediting treatment, and reducing costs, are already changing healthcare, and future results are anticipated to be even better.

Rapid technological advancements enable the early identification and diagnosis of diseases, shifting the focus of diagnostics from the disease state to a healthy life. Artificial Intelligence (AI) systems can help with a variety of tasks, including diagnosis and treatment, and have the potential to lower human errors. Visual pattern recognition software, whose early findings indicate similar accuracy as medical professionals, is a significant use of AI.

Elevate Your Understanding with PDF Sample Downloads. @
https://www.futuremarketinsights.com/reports/sample/rep-gb-17181

Governments all throughout the world have implemented various screening programs for their populations in higher-risk groups, placing a stronger emphasis on prevention. Breast, colon, and cervical cancer screenings are a few examples. Although these screening initiatives can be quite successful at identifying diseases earlier on, it is important to consider their psychological and financial effects as well.

Overall, these factors are contributing to the growth of the Protein Diagnostics market, and are expected to continue to drive demand for effective and innovative treatment options in the coming years.

Key Takeaways:

• Reagent Kits are the leading segment of products among end users and held about 62.3% market share in 2022, the growing number of infectious diseases has led to their high adoption of reagent kits.
• By sample, serum is the most compatible because it is an abundant source of protein, accessibility, and stability than other samples. The segment contributes 35.4% value share to the global market in 2022.
• Disease diagnosis held the dominant market share of 85.0% among other applications in 2022, due to the recent rise of infectious diseases and hospital-acquired infections.
• Turbidimetry held a market share of 76.3% in 2022, owing to the factor that it shortens the assay time by enabling faster binding of the antibodies and antigen
• Hospital segment by end user accounted for a revenue share of 36.9% in the global market at the end of 2022. Hospitals are built to provide coordinated care across departments and specializations, which can be useful when many diagnostic tests are required to reach a diagnosis.
• By region, North America is leading in the global Protein Diagnostics market and is expected to continue to do so with a projected CAGR rate of 6.7% during the forecasted years.

“Increasing adoption of protein diagnostic testing for the identification of underlying diseases and early detection of chronic disease are the key drivers of the Protein Diagnostics market,” says an analyst at Future Market Insights (FMI).

Market Competition:

To expand their market share, major players in the Protein Diagnostics industry are adopting various growth strategies, including acquisitions, mergers, collaborations, and partnerships. These companies are also focused on enhancing their sales efforts and developing innovative products by leveraging new technologies.

• In October 2022, StoCastic, LLC, a premier artificial intelligence startup that delivers evidence-based decision support for hospital emergency departments (ED), has been acquired by Beckman Coulter Diagnostics.
• Biognosys, a prominent provider of next-generation proteomics technologies for drug discovery and development, reported in April 2021 that it has engaged in a strategic partnership with Siemens Healthineers, a multinational medical technology business, through its clinical laboratory in Berkeley, California. Biognosys’ expertise in unbiased biomarker discovery methods and solutions is combined with Siemens Healthineers’ skills in biomarker assay development, laboratory testing, and commercialization.

Embrace smarter choices with our methodology-derived insights today.@
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-17181

Key Players:

Beckman Coulter, Inc., Siemens Healthineers, F. Hoffmann-La Roche Ltd., Agilent Technologies, Inc. Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Elabscience Biotechnology Inc., Goldsite Diagnostics Inc., Getein Biotech, Inc., Randox Laboratories Ltd., Hipro Biotechnology Co., Ltd., and Beijing Strong Biotechnologies, Inc

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the Protein Diagnostics market in its latest study, presenting a historical demand assessment of 2017 to 2022 and projections for 2023 to 2033. The global Protein Diagnostics market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Key Segments Covered:

By Product:

• Analyzers
• Reagents

• • Albumin Test Kits
  • Alpha-1-Microglobulin Albumin Test Kits
  • Alpha-2-Macroglobulin Albumin Test Kits
  • C-Reactive Protein Test Kits
  • Fibrinogen Test Kits
  • Fibronectin Test Kits
  • Haptoglobin Test Kits
  • Kappa Light Chains Kits
  • Lambda Light Chains Kits
  • Transferrin Test Kits
  • Alpha-1-Acid Glycoprotein Test Kits
  • Alpha-1-Antitrypsin Test Kits
  • Apolipoprotein B Test Kits
  • Cystatin Test Kits
  • Ferritin Test Kits
  • Immunoglobulin Test Kits

• • • IgA
    • IgE
    • IgG
    • IgG 1
    • IgG 2
    • IgG 3
    • IgG 4
    • IgM
• Lipoprotein Test Kits
• Others
• Calibrators & Controls Kits/Reagents

By Sample:

• Serum
• Plasma
• Urine
• Cerebrospinal Fluid
• Others

By Application:

• Drug Discovery and Development

• • Antigen-Antibody Reaction
  • Immunocomplex Reaction
  • Protein Measurement
  • Others
• Disease Diagnosis
  • Cancer
  • Infectious Disease
  • Blood Coagulation
  • Renal Function
  • Liver Diseases
  • Autoimmune Disorder
  • Others
• Other Applications

By Technology:

• Turbidimetry
• Nephelometry

By End User:

• Hospital
• Diagnostic Labs
• Reference Labs
• Speciality Clinics/Standalone

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:          

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube